Adherence to and Persistence with Disease-Modifying Therapies for Multiple Sclerosis Over 24 Months: A Retrospective Claims Analysis

INTRODUCTION: We sought to assess adherence to and persistence with ocrelizumab (OCR) compared with other disease-modifying treatments (DMTs), by route of administration (RoA), for multiple sclerosis (MS) after 24 months in the United States. METHODS: This retrospective claims analysis of MS patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Pardo, Gabriel, Pineda, Elmor D., Ng, Carmen D., Bawa, Komal K., Sheinson, Daniel, Bonine, Nicole G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857349/
https://www.ncbi.nlm.nih.gov/pubmed/35020156
http://dx.doi.org/10.1007/s40120-021-00319-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857349/
https://www.ncbi.nlm.nih.gov/pubmed/35020156
http://dx.doi.org/10.1007/s40120-021-00319-3

Ejemplares similares